Redmile Group, LLC Seagen Inc. Transaction History

Redmile Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $44.9 Million - $74 Million	412,739 Added 93.53%	854,013 $151 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $8.31 Million - $11 Million	69,435 Added 18.67%	441,274 $63.6 Million
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $30.7 Million - $41.1 Million	-215,535 Reduced 36.69%	371,839 $57.5 Million
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $26.2 Million - $31.2 Million	-184,011 Reduced 23.85%	587,374 $99.7 Million
Q2 2021 Aug 16, 2021	SELL	$135.08 - $161.1 $22.4 Million - $26.7 Million	-165,660 Reduced 17.68%	771,385 $122 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $129 Million - $179 Million	937,045 New	937,045 $130 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.